RE:RE:RE:huh?Hi Eoganacht patients 21-24 were announced August 30/2021 in receiving their primary treatment so they have only reached 360 days which would mean they along with patient 25 will then reach 450 by mid to end of December, if that's the case then the CR percent will be greater as those 5 represent 20% of the Phase2 population. My assumption here is when new patients are announced they have primary treatment but have not reached their 90 day target, am I wrong?
Eoganacht wrote
In December we should see the submission of the 450 day results for the first 25 patients. We already know the results for the first 24. Currently the 450 day CR rate is 21%. If the 25th patient is CR this will be a CR rate of 24% And if the 3 PR patients are converted to CR this will be a CR rate of 36%.
These results, along with the better results of the patients who have not yet reached 450 days, the patient friendly 2 dose protocol and the high safety profile, should be enough for BTD and AA IMHO.
Keytruda was approved by the FDA for treatment of BCG-unresponsive NMIBC with only a 19% CR rate at 12 months, multiple treatments (every 3 weeks for up to 24 months) and 67% treatment related adverse events.
In contrast, the TLD1433 trial has only seen 19% of the 42 patients with serious adverse effects and Theralase believes that none of them are treatment related. Scorpio2 wrote: We could get news on the vaccine front anytime in October.
But, the real biggie will be the Phase 2 ACT trial update anytime in December.